nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K1—embryo—muscle cancer	0.0141	0.115	CbGeAlD
Trametinib—MAP2K1—smooth muscle tissue—muscle cancer	0.0111	0.0907	CbGeAlD
Trametinib—MAP2K1—renal system—muscle cancer	0.0106	0.0873	CbGeAlD
Trametinib—MAP2K2—smooth muscle tissue—muscle cancer	0.00973	0.0798	CbGeAlD
Trametinib—MAP2K2—renal system—muscle cancer	0.00937	0.0769	CbGeAlD
Trametinib—MAP2K2—cardiac atrium—muscle cancer	0.00839	0.0688	CbGeAlD
Trametinib—MAP2K1—bone marrow—muscle cancer	0.00805	0.066	CbGeAlD
Trametinib—MAP2K2—tendon—muscle cancer	0.00731	0.06	CbGeAlD
Trametinib—MAP2K1—head—muscle cancer	0.00712	0.0584	CbGeAlD
Trametinib—MAP2K2—bone marrow—muscle cancer	0.00708	0.0581	CbGeAlD
Trametinib—MAP2K1—testis—muscle cancer	0.00688	0.0564	CbGeAlD
Trametinib—CYP2C8—Etoposide—muscle cancer	0.00628	0.471	CbGbCtD
Trametinib—MAP2K2—head—muscle cancer	0.00627	0.0514	CbGeAlD
Trametinib—MAP2K2—testis—muscle cancer	0.00606	0.0497	CbGeAlD
Trametinib—CYP2C8—renal system—muscle cancer	0.00324	0.0266	CbGeAlD
Trametinib—CYP3A4—Vincristine—muscle cancer	0.00278	0.208	CbGbCtD
Trametinib—CYP3A4—Etoposide—muscle cancer	0.00255	0.191	CbGbCtD
Trametinib—CYP2C8—vagina—muscle cancer	0.00235	0.0193	CbGeAlD
Trametinib—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.00234	0.00556	CcSEcCtD
Trametinib—Cardiac failure congestive—Etoposide—muscle cancer	0.00232	0.00552	CcSEcCtD
Trametinib—Cyst—Doxorubicin—muscle cancer	0.00225	0.00535	CcSEcCtD
Trametinib—CYP3A4—renal system—muscle cancer	0.0022	0.018	CbGeAlD
Trametinib—Stomatitis—Dactinomycin—muscle cancer	0.00218	0.0052	CcSEcCtD
Trametinib—Hypercalcaemia—Doxorubicin—muscle cancer	0.00216	0.00515	CcSEcCtD
Trametinib—CYP2C8—testis—muscle cancer	0.0021	0.0172	CbGeAlD
Trametinib—Neutropenia—Vincristine—muscle cancer	0.0021	0.00499	CcSEcCtD
Trametinib—Vaginal haemorrhage—Doxorubicin—muscle cancer	0.00203	0.00483	CcSEcCtD
Trametinib—Rash erythematous—Doxorubicin—muscle cancer	0.00196	0.00467	CcSEcCtD
Trametinib—Stomatitis—Vincristine—muscle cancer	0.00195	0.00464	CcSEcCtD
Trametinib—Bone disorder—Methotrexate—muscle cancer	0.00192	0.00457	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Methotrexate—muscle cancer	0.00191	0.00454	CcSEcCtD
Trametinib—MAP2K2—B Cell Receptor Signaling Pathway—FOXO1—muscle cancer	0.0019	0.00428	CbGpPWpGaD
Trametinib—Rash pustular—Doxorubicin—muscle cancer	0.00188	0.00448	CcSEcCtD
Trametinib—MAP2K1—VEGFR2 mediated cell proliferation—VEGFA—muscle cancer	0.00188	0.00422	CbGpPWpGaD
Trametinib—MAP2K1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	0.00187	0.00421	CbGpPWpGaD
Trametinib—Alanine aminotransferase increased—Etoposide—muscle cancer	0.00185	0.00442	CcSEcCtD
Trametinib—MAP2K2—BDNF signaling pathway—CNR1—muscle cancer	0.00184	0.00415	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—FOXO4—muscle cancer	0.00183	0.00411	CbGpPWpGaD
Trametinib—Chills—Dactinomycin—muscle cancer	0.0018	0.00429	CcSEcCtD
Trametinib—MAP2K2—Signaling by ERBB4—FOXO4—muscle cancer	0.0018	0.00404	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—FOXO4—muscle cancer	0.00179	0.00402	CbGpPWpGaD
Trametinib—MAP2K1—B Cell Receptor Signaling Pathway—FOXO1—muscle cancer	0.00178	0.004	CbGpPWpGaD
Trametinib—Urinary tract disorder—Vincristine—muscle cancer	0.00177	0.00422	CcSEcCtD
Trametinib—Connective tissue disorder—Vincristine—muscle cancer	0.00176	0.0042	CcSEcCtD
Trametinib—Urethral disorder—Vincristine—muscle cancer	0.00176	0.00419	CcSEcCtD
Trametinib—Neoplasm malignant—Doxorubicin—muscle cancer	0.00176	0.00419	CcSEcCtD
Trametinib—Erythema—Dactinomycin—muscle cancer	0.00175	0.00417	CcSEcCtD
Trametinib—CYP3A4—Doxorubicin—muscle cancer	0.00174	0.13	CbGbCtD
Trametinib—MAP2K1—BDNF signaling pathway—CNR1—muscle cancer	0.00173	0.00388	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—FOXO4—muscle cancer	0.00172	0.00386	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—FOXO4—muscle cancer	0.00171	0.00385	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	0.00171	0.00384	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—FOXO4—muscle cancer	0.00171	0.00384	CbGpPWpGaD
Trametinib—MAP2K1—ErbB Signaling Pathway—MDM2—muscle cancer	0.00171	0.00384	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—FOXO4—muscle cancer	0.0017	0.00382	CbGpPWpGaD
Trametinib—Neutropenia—Etoposide—muscle cancer	0.0017	0.00405	CcSEcCtD
Trametinib—MAP2K2—DAP12 signaling—FOXO4—muscle cancer	0.00169	0.00381	CbGpPWpGaD
Trametinib—Melaena—Methotrexate—muscle cancer	0.00169	0.00403	CcSEcCtD
Trametinib—MAP2K1—Signaling by ERBB4—FOXO4—muscle cancer	0.00168	0.00378	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MYOG—muscle cancer	0.00167	0.00375	CbGpPWpGaD
Trametinib—Cardiac disorder—Vincristine—muscle cancer	0.00167	0.00397	CcSEcCtD
Trametinib—Rectal haemorrhage—Doxorubicin—muscle cancer	0.00166	0.00396	CcSEcCtD
Trametinib—Bone disorder—Doxorubicin—muscle cancer	0.00166	0.00396	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Doxorubicin—muscle cancer	0.00165	0.00393	CcSEcCtD
Trametinib—Cellulitis—Doxorubicin—muscle cancer	0.00165	0.00393	CcSEcCtD
Trametinib—Hypocalcaemia—Doxorubicin—muscle cancer	0.00164	0.00391	CcSEcCtD
Trametinib—MAP2K2—Bladder Cancer—TP53—muscle cancer	0.00163	0.00367	CbGpPWpGaD
Trametinib—Angiopathy—Vincristine—muscle cancer	0.00163	0.00388	CcSEcCtD
Trametinib—Infestation NOS—Etoposide—muscle cancer	0.00162	0.00386	CcSEcCtD
Trametinib—Infestation—Etoposide—muscle cancer	0.00162	0.00386	CcSEcCtD
Trametinib—Mediastinal disorder—Vincristine—muscle cancer	0.00162	0.00385	CcSEcCtD
Trametinib—Anaemia—Dactinomycin—muscle cancer	0.00162	0.00385	CcSEcCtD
Trametinib—MAP2K1—Downstream signal transduction—FOXO4—muscle cancer	0.00161	0.00361	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—FOXO4—muscle cancer	0.0016	0.0036	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	0.0016	0.0036	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—FOXO4—muscle cancer	0.00159	0.00358	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—FOXO4—muscle cancer	0.00159	0.00358	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.00159	0.00358	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—FOXO4—muscle cancer	0.00159	0.00358	CbGpPWpGaD
Trametinib—Renal failure—Etoposide—muscle cancer	0.00159	0.00379	CcSEcCtD
Trametinib—MAP2K1—DAP12 signaling—FOXO4—muscle cancer	0.00158	0.00356	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—FOXO4—muscle cancer	0.00158	0.00355	CbGpPWpGaD
Trametinib—Stomatitis—Etoposide—muscle cancer	0.00158	0.00376	CcSEcCtD
Trametinib—Creatinine increased—Doxorubicin—muscle cancer	0.00158	0.00376	CcSEcCtD
Trametinib—Mental disorder—Vincristine—muscle cancer	0.00157	0.00375	CcSEcCtD
Trametinib—Mouth ulceration—Methotrexate—muscle cancer	0.00157	0.00373	CcSEcCtD
Trametinib—Neoplasm—Methotrexate—muscle cancer	0.00157	0.00373	CcSEcCtD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—FOXO4—muscle cancer	0.00157	0.00352	CbGpPWpGaD
Trametinib—Leukopenia—Dactinomycin—muscle cancer	0.00156	0.00373	CcSEcCtD
Trametinib—MAP2K1—Developmental Biology—MYOG—muscle cancer	0.00156	0.00351	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—FOXO4—muscle cancer	0.00156	0.0035	CbGpPWpGaD
Trametinib—MAP2K1—Bladder Cancer—TP53—muscle cancer	0.00153	0.00343	CbGpPWpGaD
Trametinib—Back pain—Vincristine—muscle cancer	0.00151	0.0036	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Doxorubicin—muscle cancer	0.0015	0.00358	CcSEcCtD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.00149	0.00335	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—FOXO4—muscle cancer	0.00149	0.00335	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—FOXO4—muscle cancer	0.00149	0.00335	CbGpPWpGaD
Trametinib—Myalgia—Dactinomycin—muscle cancer	0.00149	0.00355	CcSEcCtD
Trametinib—MAP2K1—Signaling by EGFR—FOXO4—muscle cancer	0.00148	0.00332	CbGpPWpGaD
Trametinib—Hyperkalaemia—Doxorubicin—muscle cancer	0.00148	0.00351	CcSEcCtD
Trametinib—MAP2K1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.00147	0.00331	CbGpPWpGaD
Trametinib—Melaena—Doxorubicin—muscle cancer	0.00147	0.00349	CcSEcCtD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—FOXO4—muscle cancer	0.00146	0.00329	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—FOXO4—muscle cancer	0.00146	0.00328	CbGpPWpGaD
Trametinib—Anaemia—Vincristine—muscle cancer	0.00144	0.00344	CcSEcCtD
Trametinib—Urinary tract disorder—Etoposide—muscle cancer	0.00144	0.00342	CcSEcCtD
Trametinib—Oedema—Dactinomycin—muscle cancer	0.00143	0.0034	CcSEcCtD
Trametinib—Urethral disorder—Etoposide—muscle cancer	0.00142	0.00339	CcSEcCtD
Trametinib—Infection—Dactinomycin—muscle cancer	0.00142	0.00338	CcSEcCtD
Trametinib—MAP2K2—Signaling by SCF-KIT—FOXO1—muscle cancer	0.00141	0.00317	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.00141	0.00317	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.0014	0.00315	CbGpPWpGaD
Trametinib—Leukopenia—Vincristine—muscle cancer	0.0014	0.00333	CcSEcCtD
Trametinib—Thrombocytopenia—Dactinomycin—muscle cancer	0.0014	0.00333	CcSEcCtD
Trametinib—MAP2K2—Amyotrophic lateral sclerosis (ALS)—TP53—muscle cancer	0.00139	0.00312	CbGpPWpGaD
Trametinib—Dry eye—Doxorubicin—muscle cancer	0.00139	0.0033	CcSEcCtD
Trametinib—Rash maculo-papular—Doxorubicin—muscle cancer	0.00136	0.00325	CcSEcCtD
Trametinib—Renal failure acute—Methotrexate—muscle cancer	0.00136	0.00325	CcSEcCtD
Trametinib—Eye disorder—Etoposide—muscle cancer	0.00136	0.00324	CcSEcCtD
Trametinib—Mouth ulceration—Doxorubicin—muscle cancer	0.00136	0.00323	CcSEcCtD
Trametinib—Neoplasm—Doxorubicin—muscle cancer	0.00136	0.00323	CcSEcCtD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—FOXO1—muscle cancer	0.00135	0.00304	CbGpPWpGaD
Trametinib—Cardiac disorder—Etoposide—muscle cancer	0.00135	0.00321	CcSEcCtD
Trametinib—Hypertension—Vincristine—muscle cancer	0.00135	0.00321	CcSEcCtD
Trametinib—MAP2K2—Signaling Pathways in Glioblastoma—CDKN2A—muscle cancer	0.00135	0.00303	CbGpPWpGaD
Trametinib—Myalgia—Vincristine—muscle cancer	0.00133	0.00317	CcSEcCtD
Trametinib—MAP2K2—Signaling by ERBB4—FOXO1—muscle cancer	0.00133	0.00299	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—FOXO1—muscle cancer	0.00132	0.00297	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.00132	0.00297	CbGpPWpGaD
Trametinib—Angiopathy—Etoposide—muscle cancer	0.00132	0.00314	CcSEcCtD
Trametinib—Mediastinal disorder—Etoposide—muscle cancer	0.00131	0.00312	CcSEcCtD
Trametinib—MAP2K2—SHP2 signaling—VEGFA—muscle cancer	0.00131	0.00294	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways in Glioblastoma—MDM2—muscle cancer	0.00131	0.00294	CbGpPWpGaD
Trametinib—Chills—Etoposide—muscle cancer	0.0013	0.00311	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.0013	0.0031	CcSEcCtD
Trametinib—MAP2K2—Insulin Signaling—FOXO1—muscle cancer	0.00128	0.00287	CbGpPWpGaD
Trametinib—Oedema—Vincristine—muscle cancer	0.00127	0.00304	CcSEcCtD
Trametinib—MAP2K2—Downstream signal transduction—FOXO1—muscle cancer	0.00127	0.00285	CbGpPWpGaD
Trametinib—Infection—Vincristine—muscle cancer	0.00127	0.00302	CcSEcCtD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—FOXO1—muscle cancer	0.00126	0.00284	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	0.00126	0.00284	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—FOXO1—muscle cancer	0.00126	0.00284	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways in Glioblastoma—CDKN2A—muscle cancer	0.00126	0.00283	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—FOXO1—muscle cancer	0.00126	0.00282	CbGpPWpGaD
Trametinib—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.00125	0.00299	CcSEcCtD
Trametinib—MAP2K2—DAP12 signaling—FOXO1—muscle cancer	0.00125	0.00281	CbGpPWpGaD
Trametinib—Nervous system disorder—Vincristine—muscle cancer	0.00125	0.00298	CcSEcCtD
Trametinib—Thrombocytopenia—Vincristine—muscle cancer	0.00125	0.00297	CcSEcCtD
Trametinib—MAP2K1—Signaling by ERBB4—FOXO1—muscle cancer	0.00124	0.00279	CbGpPWpGaD
Trametinib—Decreased appetite—Dactinomycin—muscle cancer	0.00124	0.00296	CcSEcCtD
Trametinib—Dysgeusia—Etoposide—muscle cancer	0.00124	0.00295	CcSEcCtD
Trametinib—Hyperhidrosis—Vincristine—muscle cancer	0.00123	0.00294	CcSEcCtD
Trametinib—Fatigue—Dactinomycin—muscle cancer	0.00123	0.00293	CcSEcCtD
Trametinib—MAP2K1—SHP2 signaling—VEGFA—muscle cancer	0.00123	0.00275	CbGpPWpGaD
Trametinib—Back pain—Etoposide—muscle cancer	0.00122	0.00292	CcSEcCtD
Trametinib—MAP2K1—Signaling Pathways in Glioblastoma—MDM2—muscle cancer	0.00122	0.00275	CbGpPWpGaD
Trametinib—Muscle spasms—Etoposide—muscle cancer	0.00122	0.0029	CcSEcCtD
Trametinib—Cardiac failure congestive—Doxorubicin—muscle cancer	0.0012	0.00286	CcSEcCtD
Trametinib—MAP2K2—Oncostatin M Signaling Pathway—VEGFA—muscle cancer	0.0012	0.00269	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—FOXO1—muscle cancer	0.00119	0.00268	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—FOXO1—muscle cancer	0.00119	0.00267	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—FOXO1—muscle cancer	0.00118	0.00266	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	0.00118	0.00266	CbGpPWpGaD
Trametinib—Renal failure acute—Doxorubicin—muscle cancer	0.00118	0.00281	CcSEcCtD
Trametinib—MAP2K2—Signaling by FGFR in disease—FOXO1—muscle cancer	0.00118	0.00264	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.00118	0.00264	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—FOXO1—muscle cancer	0.00118	0.00264	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—FOXO1—muscle cancer	0.00118	0.00264	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—FOXO1—muscle cancer	0.00117	0.00263	CbGpPWpGaD
Trametinib—Anaemia—Etoposide—muscle cancer	0.00117	0.00279	CcSEcCtD
Trametinib—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.00117	0.00263	CbGpPWpGaD
Trametinib—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00117	0.00278	CcSEcCtD
Trametinib—MAP2K2—Signaling by EGFR—FOXO1—muscle cancer	0.00117	0.00262	CbGpPWpGaD
Trametinib—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00116	0.00277	CcSEcCtD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.00116	0.0026	CbGpPWpGaD
Trametinib—Insomnia—Vincristine—muscle cancer	0.00115	0.00275	CcSEcCtD
Trametinib—MAP2K2—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—muscle cancer	0.00115	0.00259	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—FOXO1—muscle cancer	0.00115	0.00259	CbGpPWpGaD
Trametinib—Leukopenia—Etoposide—muscle cancer	0.00113	0.0027	CcSEcCtD
Trametinib—Body temperature increased—Dactinomycin—muscle cancer	0.00113	0.00269	CcSEcCtD
Trametinib—Abdominal pain—Dactinomycin—muscle cancer	0.00113	0.00269	CcSEcCtD
Trametinib—MAP2K1—Oncostatin M Signaling Pathway—VEGFA—muscle cancer	0.00112	0.00251	CbGpPWpGaD
Trametinib—Decreased appetite—Vincristine—muscle cancer	0.00111	0.00264	CcSEcCtD
Trametinib—Cough—Etoposide—muscle cancer	0.0011	0.00263	CcSEcCtD
Trametinib—MAP2K1—Signaling by FGFR in disease—FOXO1—muscle cancer	0.0011	0.00247	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.0011	0.00247	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—FOXO1—muscle cancer	0.0011	0.00247	CbGpPWpGaD
Trametinib—Gastrointestinal disorder—Vincristine—muscle cancer	0.0011	0.00262	CcSEcCtD
Trametinib—Fatigue—Vincristine—muscle cancer	0.0011	0.00262	CcSEcCtD
Trametinib—Hyponatraemia—Doxorubicin—muscle cancer	0.00109	0.00261	CcSEcCtD
Trametinib—Hypertension—Etoposide—muscle cancer	0.00109	0.0026	CcSEcCtD
Trametinib—MAP2K1—Signaling by EGFR—FOXO1—muscle cancer	0.00109	0.00245	CbGpPWpGaD
Trametinib—Constipation—Vincristine—muscle cancer	0.00109	0.0026	CcSEcCtD
Trametinib—Pain in extremity—Doxorubicin—muscle cancer	0.00109	0.0026	CcSEcCtD
Trametinib—MAP2K2—Signaling by NGF—FOXO4—muscle cancer	0.00109	0.00244	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.00108	0.00243	CbGpPWpGaD
Trametinib—MAP2K1—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—muscle cancer	0.00108	0.00242	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—FOXO1—muscle cancer	0.00108	0.00242	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—KIT—muscle cancer	0.00108	0.00242	CbGpPWpGaD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00107	0.00255	CcSEcCtD
Trametinib—Pancreatitis—Methotrexate—muscle cancer	0.00107	0.00254	CcSEcCtD
Trametinib—Abdominal discomfort—Methotrexate—muscle cancer	0.00104	0.00248	CcSEcCtD
Trametinib—Gastrointestinal pain—Vincristine—muscle cancer	0.00104	0.00248	CcSEcCtD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.00104	0.00234	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	0.00103	0.00232	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MYOD1—muscle cancer	0.00103	0.00232	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—KIT—muscle cancer	0.00103	0.00231	CbGpPWpGaD
Trametinib—Infection—Etoposide—muscle cancer	0.00103	0.00244	CcSEcCtD
Trametinib—Asthenia—Dactinomycin—muscle cancer	0.00102	0.00244	CcSEcCtD
Trametinib—Blood creatinine increased—Doxorubicin—muscle cancer	0.00102	0.00243	CcSEcCtD
Trametinib—Neutropenia—Methotrexate—muscle cancer	0.00102	0.00242	CcSEcCtD
Trametinib—MAP2K1—Signaling by NGF—FOXO4—muscle cancer	0.00102	0.00228	CbGpPWpGaD
Trametinib—Dehydration—Doxorubicin—muscle cancer	0.00101	0.00241	CcSEcCtD
Trametinib—MAP2K2—Signaling by ERBB4—KIT—muscle cancer	0.00101	0.00228	CbGpPWpGaD
Trametinib—Thrombocytopenia—Etoposide—muscle cancer	0.00101	0.00241	CcSEcCtD
Trametinib—Abdominal pain—Vincristine—muscle cancer	0.00101	0.0024	CcSEcCtD
Trametinib—Body temperature increased—Vincristine—muscle cancer	0.00101	0.0024	CcSEcCtD
Trametinib—MAP2K1—Signaling by SCF-KIT—KIT—muscle cancer	0.00101	0.00226	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—MDM2—muscle cancer	0.001	0.00225	CbGpPWpGaD
Trametinib—Skin disorder—Etoposide—muscle cancer	0.001	0.00239	CcSEcCtD
Trametinib—Dry skin—Doxorubicin—muscle cancer	0.000999	0.00238	CcSEcCtD
Trametinib—Hyperhidrosis—Etoposide—muscle cancer	0.000998	0.00238	CcSEcCtD
Trametinib—Abdominal pain upper—Doxorubicin—muscle cancer	0.000995	0.00237	CcSEcCtD
Trametinib—Hypokalaemia—Doxorubicin—muscle cancer	0.000992	0.00236	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000981	0.00234	CcSEcCtD
Trametinib—MAP2K1—ErbB Signaling Pathway—TP53—muscle cancer	0.00098	0.0022	CbGpPWpGaD
Trametinib—Diarrhoea—Dactinomycin—muscle cancer	0.000976	0.00233	CcSEcCtD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.000975	0.00219	CbGpPWpGaD
Trametinib—Infestation NOS—Methotrexate—muscle cancer	0.00097	0.00231	CcSEcCtD
Trametinib—Infestation—Methotrexate—muscle cancer	0.00097	0.00231	CcSEcCtD
Trametinib—MAP2K2—Downstream signal transduction—KIT—muscle cancer	0.000967	0.00217	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MYOD1—muscle cancer	0.000965	0.00217	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—KIT—muscle cancer	0.000963	0.00216	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—KIT—muscle cancer	0.000963	0.00216	CbGpPWpGaD
Trametinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000961	0.00229	CcSEcCtD
Trametinib—MAP2K2—Signaling by ERBB2—KIT—muscle cancer	0.000958	0.00215	CbGpPWpGaD
Trametinib—Renal failure—Methotrexate—muscle cancer	0.000953	0.00227	CcSEcCtD
Trametinib—MAP2K2—DAP12 signaling—KIT—muscle cancer	0.000953	0.00214	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—KIT—muscle cancer	0.000948	0.00213	CbGpPWpGaD
Trametinib—Stomatitis—Methotrexate—muscle cancer	0.000945	0.00225	CcSEcCtD
Trametinib—MAP2K2—Developmental Biology—MED12—muscle cancer	0.000943	0.00212	CbGpPWpGaD
Trametinib—Haematuria—Methotrexate—muscle cancer	0.000925	0.0022	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—muscle cancer	0.000923	0.0022	CcSEcCtD
Trametinib—Epistaxis—Methotrexate—muscle cancer	0.000915	0.00218	CcSEcCtD
Trametinib—Asthenia—Vincristine—muscle cancer	0.000915	0.00218	CcSEcCtD
Trametinib—Vomiting—Dactinomycin—muscle cancer	0.000907	0.00216	CcSEcCtD
Trametinib—MAP2K1—Downstream signal transduction—KIT—muscle cancer	0.000905	0.00203	CbGpPWpGaD
Trametinib—MAP2K2—Oncostatin M Signaling Pathway—TP53—muscle cancer	0.000903	0.00203	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—KIT—muscle cancer	0.000901	0.00202	CbGpPWpGaD
Trametinib—Rash—Dactinomycin—muscle cancer	0.0009	0.00214	CcSEcCtD
Trametinib—Decreased appetite—Etoposide—muscle cancer	0.000898	0.00214	CcSEcCtD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000897	0.00202	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—KIT—muscle cancer	0.000897	0.00202	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—KIT—muscle cancer	0.000897	0.00202	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—KIT—muscle cancer	0.000896	0.00201	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—KIT—muscle cancer	0.000892	0.002	CbGpPWpGaD
Trametinib—Gastrointestinal disorder—Etoposide—muscle cancer	0.000892	0.00212	CcSEcCtD
Trametinib—Fatigue—Etoposide—muscle cancer	0.00089	0.00212	CcSEcCtD
Trametinib—MAP2K2—Signaling by EGFR—KIT—muscle cancer	0.000889	0.002	CbGpPWpGaD
Trametinib—Constipation—Etoposide—muscle cancer	0.000883	0.0021	CcSEcCtD
Trametinib—MAP2K1—Developmental Biology—MED12—muscle cancer	0.000883	0.00198	CbGpPWpGaD
Trametinib—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000881	0.00198	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000881	0.00198	CbGpPWpGaD
Trametinib—Neutropenia—Doxorubicin—muscle cancer	0.000881	0.0021	CcSEcCtD
Trametinib—MAP2K2—Signaling by PDGF—KIT—muscle cancer	0.000877	0.00197	CbGpPWpGaD
Trametinib—Haemoglobin—Methotrexate—muscle cancer	0.000875	0.00208	CcSEcCtD
Trametinib—Diarrhoea—Vincristine—muscle cancer	0.000872	0.00208	CcSEcCtD
Trametinib—Haemorrhage—Methotrexate—muscle cancer	0.000871	0.00207	CcSEcCtD
Trametinib—Urinary tract disorder—Methotrexate—muscle cancer	0.00086	0.00205	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—muscle cancer	0.000853	0.00203	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—muscle cancer	0.00085	0.00202	CcSEcCtD
Trametinib—Nausea—Dactinomycin—muscle cancer	0.000848	0.00202	CcSEcCtD
Trametinib—MAP2K2—Signaling by SCF-KIT—MDM2—muscle cancer	0.000847	0.0019	CbGpPWpGaD
Trametinib—MAP2K1—Oncostatin M Signaling Pathway—TP53—muscle cancer	0.000845	0.0019	CbGpPWpGaD
Trametinib—Gastrointestinal pain—Etoposide—muscle cancer	0.000844	0.00201	CcSEcCtD
Trametinib—Dizziness—Vincristine—muscle cancer	0.000843	0.00201	CcSEcCtD
Trametinib—Infestation—Doxorubicin—muscle cancer	0.00084	0.002	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—muscle cancer	0.00084	0.002	CcSEcCtD
Trametinib—MAP2K1—Signaling by FGFR in disease—KIT—muscle cancer	0.000839	0.00189	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—KIT—muscle cancer	0.000839	0.00189	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000839	0.00189	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—KIT—muscle cancer	0.000832	0.00187	CbGpPWpGaD
Trametinib—Renal failure—Doxorubicin—muscle cancer	0.000826	0.00197	CcSEcCtD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000824	0.00185	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—KIT—muscle cancer	0.000821	0.00184	CbGpPWpGaD
Trametinib—Stomatitis—Doxorubicin—muscle cancer	0.000819	0.00195	CcSEcCtD
Trametinib—Abdominal pain—Etoposide—muscle cancer	0.000816	0.00194	CcSEcCtD
Trametinib—Body temperature increased—Etoposide—muscle cancer	0.000816	0.00194	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—muscle cancer	0.000816	0.00194	CcSEcCtD
Trametinib—Eye disorder—Methotrexate—muscle cancer	0.000814	0.00194	CcSEcCtD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000811	0.00182	CbGpPWpGaD
Trametinib—Vomiting—Vincristine—muscle cancer	0.000811	0.00193	CcSEcCtD
Trametinib—Cardiac disorder—Methotrexate—muscle cancer	0.000808	0.00193	CcSEcCtD
Trametinib—Rash—Vincristine—muscle cancer	0.000804	0.00192	CcSEcCtD
Trametinib—Dermatitis—Vincristine—muscle cancer	0.000803	0.00191	CcSEcCtD
Trametinib—MAP2K2—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.000802	0.0018	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—FOXO1—muscle cancer	0.000802	0.0018	CbGpPWpGaD
Trametinib—Haematuria—Doxorubicin—muscle cancer	0.000801	0.00191	CcSEcCtD
Trametinib—Headache—Vincristine—muscle cancer	0.000799	0.0019	CcSEcCtD
Trametinib—MAP2K2—Signaling by ERBB4—MDM2—muscle cancer	0.000798	0.00179	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000794	0.00178	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—MDM2—muscle cancer	0.000793	0.00178	CbGpPWpGaD
Trametinib—Epistaxis—Doxorubicin—muscle cancer	0.000792	0.00189	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—muscle cancer	0.00079	0.00188	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—muscle cancer	0.000785	0.00187	CcSEcCtD
Trametinib—Chills—Methotrexate—muscle cancer	0.000781	0.00186	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—muscle cancer	0.000768	0.00183	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—muscle cancer	0.000763	0.00182	CcSEcCtD
Trametinib—MAP2K2—Downstream signal transduction—MDM2—muscle cancer	0.000762	0.00171	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000758	0.0017	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—MDM2—muscle cancer	0.000758	0.0017	CbGpPWpGaD
Trametinib—Malnutrition—Methotrexate—muscle cancer	0.000758	0.00181	CcSEcCtD
Trametinib—Erythema—Methotrexate—muscle cancer	0.000758	0.00181	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—muscle cancer	0.000758	0.00181	CcSEcCtD
Trametinib—MAP2K2—Signaling by VEGF—VEGFA—muscle cancer	0.000757	0.0017	CbGpPWpGaD
Trametinib—Nausea—Vincristine—muscle cancer	0.000757	0.0018	CcSEcCtD
Trametinib—MAP2K2—Signaling by ERBB2—MDM2—muscle cancer	0.000754	0.0017	CbGpPWpGaD
Trametinib—Haemorrhage—Doxorubicin—muscle cancer	0.000754	0.0018	CcSEcCtD
Trametinib—MAP2K2—DAP12 signaling—MDM2—muscle cancer	0.000751	0.00169	CbGpPWpGaD
Trametinib—MAP2K1—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.000751	0.00169	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—FOXO1—muscle cancer	0.00075	0.00169	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways in Glioblastoma—TP53—muscle cancer	0.00075	0.00169	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—MDM2—muscle cancer	0.000746	0.00168	CbGpPWpGaD
Trametinib—Urinary tract disorder—Doxorubicin—muscle cancer	0.000745	0.00177	CcSEcCtD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000743	0.00167	CbGpPWpGaD
Trametinib—Oedema peripheral—Doxorubicin—muscle cancer	0.000743	0.00177	CcSEcCtD
Trametinib—Dysgeusia—Methotrexate—muscle cancer	0.000742	0.00177	CcSEcCtD
Trametinib—Asthenia—Etoposide—muscle cancer	0.000741	0.00177	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—muscle cancer	0.000741	0.00177	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—muscle cancer	0.000739	0.00176	CcSEcCtD
Trametinib—Back pain—Methotrexate—muscle cancer	0.000733	0.00175	CcSEcCtD
Trametinib—Pruritus—Etoposide—muscle cancer	0.000731	0.00174	CcSEcCtD
Trametinib—Vision blurred—Methotrexate—muscle cancer	0.000714	0.0017	CcSEcCtD
Trametinib—MAP2K1—Downstream signal transduction—MDM2—muscle cancer	0.000713	0.0016	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—MDM2—muscle cancer	0.000709	0.00159	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by VEGF—VEGFA—muscle cancer	0.000708	0.00159	CbGpPWpGaD
Trametinib—Diarrhoea—Etoposide—muscle cancer	0.000707	0.00168	CcSEcCtD
Trametinib—MAP2K2—DAP12 interactions—MDM2—muscle cancer	0.000706	0.00159	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000706	0.00159	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—MDM2—muscle cancer	0.000706	0.00159	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—MDM2—muscle cancer	0.000706	0.00159	CbGpPWpGaD
Trametinib—Eye disorder—Doxorubicin—muscle cancer	0.000705	0.00168	CcSEcCtD
Trametinib—MAP2K1—DAP12 signaling—MDM2—muscle cancer	0.000702	0.00158	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways in Glioblastoma—TP53—muscle cancer	0.000702	0.00158	CbGpPWpGaD
Trametinib—Anaemia—Methotrexate—muscle cancer	0.000701	0.00167	CcSEcCtD
Trametinib—MAP2K2—Signaling by EGFR—MDM2—muscle cancer	0.0007	0.00157	CbGpPWpGaD
Trametinib—Cardiac disorder—Doxorubicin—muscle cancer	0.0007	0.00167	CcSEcCtD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000694	0.00156	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—MDM2—muscle cancer	0.000691	0.00155	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KIDINS220—muscle cancer	0.000689	0.00155	CbGpPWpGaD
Trametinib—Angiopathy—Doxorubicin—muscle cancer	0.000684	0.00163	CcSEcCtD
Trametinib—Dizziness—Etoposide—muscle cancer	0.000683	0.00163	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—muscle cancer	0.000679	0.00162	CcSEcCtD
Trametinib—Leukopenia—Methotrexate—muscle cancer	0.000678	0.00162	CcSEcCtD
Trametinib—Chills—Doxorubicin—muscle cancer	0.000676	0.00161	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—muscle cancer	0.000673	0.0016	CcSEcCtD
Trametinib—Cough—Methotrexate—muscle cancer	0.000661	0.00158	CcSEcCtD
Trametinib—MAP2K1—Signaling by FGFR in disease—MDM2—muscle cancer	0.000661	0.00148	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000661	0.00148	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—MDM2—muscle cancer	0.000661	0.00148	CbGpPWpGaD
Trametinib—Mental disorder—Doxorubicin—muscle cancer	0.00066	0.00157	CcSEcCtD
Trametinib—Vomiting—Etoposide—muscle cancer	0.000657	0.00156	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—muscle cancer	0.000656	0.00156	CcSEcCtD
Trametinib—Erythema—Doxorubicin—muscle cancer	0.000656	0.00156	CcSEcCtD
Trametinib—MAP2K1—Signaling by EGFR—MDM2—muscle cancer	0.000655	0.00147	CbGpPWpGaD
Trametinib—Rash—Etoposide—muscle cancer	0.000651	0.00155	CcSEcCtD
Trametinib—Dermatitis—Etoposide—muscle cancer	0.000651	0.00155	CcSEcCtD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000649	0.00146	CbGpPWpGaD
Trametinib—Headache—Etoposide—muscle cancer	0.000647	0.00154	CcSEcCtD
Trametinib—MAP2K1—Signaling by PDGF—MDM2—muscle cancer	0.000646	0.00145	CbGpPWpGaD
Trametinib—Myalgia—Methotrexate—muscle cancer	0.000645	0.00154	CcSEcCtD
Trametinib—Arthralgia—Methotrexate—muscle cancer	0.000645	0.00154	CcSEcCtD
Trametinib—MAP2K1—Signaling Pathways—KIDINS220—muscle cancer	0.000644	0.00145	CbGpPWpGaD
Trametinib—Dysgeusia—Doxorubicin—muscle cancer	0.000643	0.00153	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000641	0.00153	CcSEcCtD
Trametinib—Back pain—Doxorubicin—muscle cancer	0.000635	0.00151	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—muscle cancer	0.000631	0.0015	CcSEcCtD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000626	0.00141	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000622	0.0014	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—FOXO4—muscle cancer	0.000619	0.00139	CbGpPWpGaD
Trametinib—Vision blurred—Doxorubicin—muscle cancer	0.000619	0.00147	CcSEcCtD
Trametinib—Infection—Methotrexate—muscle cancer	0.000615	0.00146	CcSEcCtD
Trametinib—Nausea—Etoposide—muscle cancer	0.000613	0.00146	CcSEcCtD
Trametinib—MAP2K2—Signaling by NGF—KIT—muscle cancer	0.000611	0.00137	CbGpPWpGaD
Trametinib—Nervous system disorder—Methotrexate—muscle cancer	0.000607	0.00145	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—muscle cancer	0.000607	0.00145	CcSEcCtD
Trametinib—Thrombocytopenia—Methotrexate—muscle cancer	0.000606	0.00144	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—muscle cancer	0.000601	0.00143	CcSEcCtD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000599	0.00135	CbGpPWpGaD
Trametinib—Hyperhidrosis—Methotrexate—muscle cancer	0.000598	0.00142	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—muscle cancer	0.000587	0.0014	CcSEcCtD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000585	0.00132	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—FOXO4—muscle cancer	0.000579	0.0013	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—TP53—muscle cancer	0.000576	0.00129	CbGpPWpGaD
Trametinib—Cough—Doxorubicin—muscle cancer	0.000573	0.00136	CcSEcCtD
Trametinib—MAP2K1—Signaling by NGF—KIT—muscle cancer	0.000572	0.00128	CbGpPWpGaD
Trametinib—Hypertension—Doxorubicin—muscle cancer	0.000567	0.00135	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000564	0.00134	CcSEcCtD
Trametinib—Insomnia—Methotrexate—muscle cancer	0.000559	0.00133	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—muscle cancer	0.000559	0.00133	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—muscle cancer	0.000559	0.00133	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000555	0.00132	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—muscle cancer	0.000546	0.0013	CcSEcCtD
Trametinib—Decreased appetite—Methotrexate—muscle cancer	0.000538	0.00128	CcSEcCtD
Trametinib—Oedema—Doxorubicin—muscle cancer	0.000536	0.00128	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000534	0.00127	CcSEcCtD
Trametinib—Fatigue—Methotrexate—muscle cancer	0.000533	0.00127	CcSEcCtD
Trametinib—Infection—Doxorubicin—muscle cancer	0.000532	0.00127	CcSEcCtD
Trametinib—MAP2K2—Immune System—CD34—muscle cancer	0.000531	0.00119	CbGpPWpGaD
Trametinib—Nervous system disorder—Doxorubicin—muscle cancer	0.000525	0.00125	CcSEcCtD
Trametinib—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.000525	0.00118	CbGpPWpGaD
Trametinib—Thrombocytopenia—Doxorubicin—muscle cancer	0.000524	0.00125	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—muscle cancer	0.00052	0.00124	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—muscle cancer	0.000518	0.00123	CcSEcCtD
Trametinib—MAP2K2—Developmental Biology—FOXO1—muscle cancer	0.000518	0.00116	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—TP53—muscle cancer	0.000512	0.00115	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—VEGFA—muscle cancer	0.000507	0.00114	CbGpPWpGaD
Trametinib—Gastrointestinal pain—Methotrexate—muscle cancer	0.000506	0.00121	CcSEcCtD
Trametinib—MAP2K1—Immune System—CD34—muscle cancer	0.000496	0.00112	CbGpPWpGaD
Trametinib—Abdominal pain—Methotrexate—muscle cancer	0.000489	0.00117	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—muscle cancer	0.000489	0.00117	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000488	0.00116	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—muscle cancer	0.000484	0.00115	CcSEcCtD
Trametinib—MAP2K1—Developmental Biology—FOXO1—muscle cancer	0.000484	0.00109	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—MDM2—muscle cancer	0.000481	0.00108	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—TP53—muscle cancer	0.000479	0.00108	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—VEGFA—muscle cancer	0.000474	0.00107	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000472	0.00106	CbGpPWpGaD
Trametinib—Decreased appetite—Doxorubicin—muscle cancer	0.000466	0.00111	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000462	0.0011	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—muscle cancer	0.000462	0.0011	CcSEcCtD
Trametinib—MAP2K2—Signaling by GPCR—PTCH1—muscle cancer	0.000459	0.00103	CbGpPWpGaD
Trametinib—Constipation—Doxorubicin—muscle cancer	0.000458	0.00109	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—FOXO1—muscle cancer	0.000457	0.00103	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—MDM2—muscle cancer	0.00045	0.00101	CbGpPWpGaD
Trametinib—Asthenia—Methotrexate—muscle cancer	0.000444	0.00106	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000438	0.00104	CcSEcCtD
Trametinib—Pruritus—Methotrexate—muscle cancer	0.000438	0.00104	CcSEcCtD
Trametinib—MAP2K1—Signaling by GPCR—PTCH1—muscle cancer	0.000429	0.000965	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—FOXO1—muscle cancer	0.000428	0.000961	CbGpPWpGaD
Trametinib—Abdominal pain—Doxorubicin—muscle cancer	0.000423	0.00101	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—muscle cancer	0.000423	0.00101	CcSEcCtD
Trametinib—Diarrhoea—Methotrexate—muscle cancer	0.000423	0.00101	CcSEcCtD
Trametinib—MAP2K2—MAPK Signaling Pathway—TP53—muscle cancer	0.000423	0.000949	CbGpPWpGaD
Trametinib—Dizziness—Methotrexate—muscle cancer	0.000409	0.000975	CcSEcCtD
Trametinib—MAP2K2—Disease—ENO2—muscle cancer	0.000408	0.000918	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000397	0.000891	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TP53—muscle cancer	0.000395	0.000888	CbGpPWpGaD
Trametinib—Vomiting—Methotrexate—muscle cancer	0.000393	0.000937	CcSEcCtD
Trametinib—Rash—Methotrexate—muscle cancer	0.00039	0.000929	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—muscle cancer	0.00039	0.000928	CcSEcCtD
Trametinib—Headache—Methotrexate—muscle cancer	0.000388	0.000923	CcSEcCtD
Trametinib—MAP2K2—Signaling by GPCR—CNR1—muscle cancer	0.000387	0.000871	CbGpPWpGaD
Trametinib—Asthenia—Doxorubicin—muscle cancer	0.000384	0.000916	CcSEcCtD
Trametinib—MAP2K1—Disease—ENO2—muscle cancer	0.000382	0.000859	CbGpPWpGaD
Trametinib—Pruritus—Doxorubicin—muscle cancer	0.000379	0.000903	CcSEcCtD
Trametinib—MAP2K2—Disease—HMGA1—muscle cancer	0.000371	0.000834	CbGpPWpGaD
Trametinib—Nausea—Methotrexate—muscle cancer	0.000367	0.000875	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—muscle cancer	0.000366	0.000873	CcSEcCtD
Trametinib—MAP2K1—Signaling by GPCR—CNR1—muscle cancer	0.000362	0.000814	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—FOXO4—muscle cancer	0.000361	0.00081	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000357	0.000802	CbGpPWpGaD
Trametinib—Dizziness—Doxorubicin—muscle cancer	0.000354	0.000844	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—KIT—muscle cancer	0.000348	0.000783	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HMGA1—muscle cancer	0.000347	0.00078	CbGpPWpGaD
Trametinib—Vomiting—Doxorubicin—muscle cancer	0.000341	0.000811	CcSEcCtD
Trametinib—Rash—Doxorubicin—muscle cancer	0.000338	0.000805	CcSEcCtD
Trametinib—MAP2K1—Immune System—FOXO4—muscle cancer	0.000337	0.000758	CbGpPWpGaD
Trametinib—Dermatitis—Doxorubicin—muscle cancer	0.000337	0.000804	CcSEcCtD
Trametinib—Headache—Doxorubicin—muscle cancer	0.000336	0.000799	CcSEcCtD
Trametinib—MAP2K2—Disease—FOXO4—muscle cancer	0.000333	0.000748	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—VEGFA—muscle cancer	0.000331	0.000743	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KIT—muscle cancer	0.000326	0.000733	CbGpPWpGaD
Trametinib—Nausea—Doxorubicin—muscle cancer	0.000318	0.000758	CcSEcCtD
Trametinib—CYP2C8—Metabolism—FH—muscle cancer	0.000313	0.000702	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FOXO4—muscle cancer	0.000312	0.0007	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—VEGFA—muscle cancer	0.000309	0.000695	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MDM2—muscle cancer	0.000274	0.000617	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTCH1—muscle cancer	0.000271	0.000609	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—FOXO1—muscle cancer	0.000266	0.000598	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MDM2—muscle cancer	0.000257	0.000577	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTCH1—muscle cancer	0.000254	0.00057	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—FOXO1—muscle cancer	0.000249	0.00056	CbGpPWpGaD
Trametinib—MAP2K2—Disease—FOXO1—muscle cancer	0.000246	0.000553	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—VEGFA—muscle cancer	0.000236	0.00053	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FOXO4—muscle cancer	0.000233	0.000524	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FOXO1—muscle cancer	0.00023	0.000517	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CNR1—muscle cancer	0.000229	0.000514	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—VEGFA—muscle cancer	0.000221	0.000496	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FOXO4—muscle cancer	0.000218	0.00049	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CNR1—muscle cancer	0.000214	0.000481	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KIT—muscle cancer	0.000203	0.000456	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KIT—muscle cancer	0.00019	0.000427	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KIT—muscle cancer	0.000187	0.000421	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF2—muscle cancer	0.000187	0.00042	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—MED12—muscle cancer	0.000177	0.000397	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KIT—muscle cancer	0.000175	0.000394	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF2—muscle cancer	0.000175	0.000393	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FOXO1—muscle cancer	0.000172	0.000387	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—FH—muscle cancer	0.000168	0.000377	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FOXO1—muscle cancer	0.000161	0.000362	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ENO2—muscle cancer	0.000161	0.000362	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MDM2—muscle cancer	0.00016	0.000359	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MDM2—muscle cancer	0.00015	0.000336	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MDM2—muscle cancer	0.000148	0.000332	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—muscle cancer	0.000142	0.00032	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MDM2—muscle cancer	0.000138	0.00031	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—muscle cancer	0.000133	0.000299	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KIT—muscle cancer	0.000131	0.000295	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.000126	0.000283	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KIT—muscle cancer	0.000123	0.000276	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MDM2—muscle cancer	0.000103	0.000232	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MDM2—muscle cancer	9.67e-05	0.000217	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MED12—muscle cancer	9.48e-05	0.000213	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ENO2—muscle cancer	8.64e-05	0.000194	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—muscle cancer	7.85e-05	0.000176	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—muscle cancer	7.34e-05	0.000165	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—muscle cancer	5.93e-05	0.000133	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—muscle cancer	5.61e-05	0.000126	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—muscle cancer	5.55e-05	0.000125	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—muscle cancer	3.01e-05	6.77e-05	CbGpPWpGaD
